Last reviewed · How we verify

2% Taurolidine Lock

Stanley Dudrick's Memorial Hospital · FDA-approved active Small molecule Quality 5/100

2% Taurolidine Lock is a Small molecule drug developed by Stanley Dudrick's Memorial Hospital. It is currently FDA-approved.

2% Taurolidine Lock, marketed by Stanley Dudrick's Memorial Hospital, is a catheter lock solution currently available in the market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its competitive position. The primary risk is the potential for increased competition once the patent expires.

At a glance

Generic name2% Taurolidine Lock
SponsorStanley Dudrick's Memorial Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about 2% Taurolidine Lock

What is 2% Taurolidine Lock?

2% Taurolidine Lock is a Small molecule drug developed by Stanley Dudrick's Memorial Hospital.

Who makes 2% Taurolidine Lock?

2% Taurolidine Lock is developed and marketed by Stanley Dudrick's Memorial Hospital (see full Stanley Dudrick's Memorial Hospital pipeline at /company/stanley-dudrick-s-memorial-hospital).

What development phase is 2% Taurolidine Lock in?

2% Taurolidine Lock is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing